Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.88) by 2.27 percent. This is a 2.27 percent decrease over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $761.000 thousand which beat the analyst consensus estimate of $258.583 thousand by 194.30 percent. This is a 294.30 percent increase over sales of $193.000 thousand the same period last year.